Issue of Equity

Deltex Medical Group PLC
25 October 2004





                            Deltex Medical Group PLC



                    Placing of 4,629,630 new ordinary shares
                             to raise £1.25 million



26 October 2003:  Deltex Medical Group PLC ('Deltex' or the 'Company') is
pleased to announce that Charles Stanley & Co Limited has placed 4,629,630 new
ordinary shares of 1p each ('New Ordinary Shares') at 27p per share to raise
£1.25 million before expenses (£1.22 million net of costs) with certain
institutional investors (the 'Placing').



The proceeds of the Placing will be used primarily to finance the further
development of the wholly non-invasive SupraQ(TM) cardiac output monitor towards 
a widely applicable, easy to use next generation device.  This process includes
protecting the Company's intellectual property interests as the technology is
developed, and obtaining the appropriate regulatory approvals for selling the
device in the Company's target markets.  The proceeds will also be used to
recruit further clinical trainers and to supplement the Company's existing
working capital facilities to meet the increased demand for its products in its
core markets.



The placing represents approximately 7.24 per cent of the existing issued share
capital of the Company.  The New Ordinary Shares will rank pari passu with
existing ordinary shares.  The Placing is conditional on admission of the New
Ordinary Shares to trading on AIM ('Admission') which is expected to take place,
and dealings are expected to commence, on 29 October 2004.



For Further Information:



Deltex Medical Group plc                           01243 774 837

Andy Hill, Chief Executive

Ewan Phillips, Finance Director



Charles Stanley & Co. Limited                      020 7739 8200

Philip Davies / Russell Cook



Financial Dynamics

David Yates / Lucy Briggs                          020 7269 7223







Notes for Editors

Deltex Medical manufactures and markets the CardioQ(TM) monitor, which uses
disposable ultrasound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ(TM), to optimise the 
amount of circulating blood significantly reduces post-operative complications 
allowing patients to make a faster, more complete recovery and return home 
earlier.



The CardioQ(TM) incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultrasound signal. By using this
technology, the CardioQ(TM) provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.


There are already over 1,250 CardioQs(TM) currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 100 clinical publications on the use of the
CardioQTM which have repeatedly:-


•    validated the results of the Monitor against known standards for
     measuring cardiac output, demonstrating that the technology works


•    proved that the CardioQTM works in a wide range of surgical procedures


•    demonstrated that the Company's technology provides significant health
     and economic benefits by helping to reduce post-operative complications and
     length of hospital stays by an average of 25 to 40 per cent for a wide 
     range of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange